From the outset of the review, the academy confirmed that there is a problem. Its survey found that only one in three members of the public trusts the results of research. It also found that more than four fifths of general practitioners and two thirds of British adults disbelieved the results of trials funded by the drug industry.
In response to this finding, which the chair of the report, John Tooke, called "startling," 4 the academy has produced a wide ranging report that says many of the right things. But the overall result is disappointing. In their 2015 editorial, Heneghan and Goldacre warned against focusing on gaining the public's trust through false assurances. 2 They proposed instead improving the evidence base through changes in the funding, conduct, and dissemination of research. The academy report includes welcome calls for researchers to involve patients and be more transparent, but its main focus (taking up half of the 12 recommendations (box 1) and the entire press release 5 ) is better communication with patients and the public. It offers few new or concrete suggestions to tackle what the UK's Science and Technology Committee identifies as a crisis in reproducibility of research and an upward trend in misconduct and mistakes. 
Missed opportunities
The BMJ has been closely involved in the four issues that triggered the report and continues to campaign on them. What does the report say about these issues, and what could it have said? A "detailed account" of the statins saga sticks to the version presented in various places by the Cholesterol Treatment Trialists collaboration. 7 The report says that future controversies could be prevented through better communication and, among other things, better access to data. But the debate about statins in people at low risk has not gone away, [8] [9] [10] [11] and the anonymised trial data remain inaccessible. The academy could have put its weight behind calls for an independent review of the evidence, 12 similar to the review on breast cancer screening commissioned by the UK's cancer tsar in 2012. 13 The report makes far less of the controversy around oseltamivir, despite this being perhaps the best illustration of why the public and professionals cannot trust the published evidence. It took five years of campaigning to get the raw data from the manufacturer, Roche. An independent review of the full trial data then found no good evidence of benefit in pandemic situations and some previously unreported harms. 14 Despite this, the UK government purchased further stockpiles, citing support from observational studies. 15 The academy could have used its position to hold Roche accountable for withholding data, undermining public trust, and wasting public money. It could also have made concrete proposals for better independent research during future pandemics.
As for overmedication, this has many causes. Most relevant to judging the benefits and harms of medicines is the optimism bias afflicting the medical literature. Poor science, research misconduct, and publication bias all contribute to the systematic exaggeration of benefit and understatement of harm. 16 Communicating this overoptimistic view more effectively will only compound the problem. But the academy's priority seems to be to reassure patients and the public so that they will take their pills, and to collaborate closely with industry to develop more. It would have been good to see the academy acknowledge the avoidable harm and cost caused by overmedication, and to propose possible solutions and avenues for further research into the problem.
Finally, on conflicts of interest, the report suggests managing these through frameworks to be developed by existing bodies. It says potentially conflicted experts should be excluded from decision making only if their interests will interfere with objectivity, and it advocates increased collaboration between academics and industry as long as safeguards are in place. In this the academy continues its support for standards below those required of judges and journalists. 17 The report looks to funders and the next research excellence framework to incentivise better research and publication practices. But the academy could also lead by example. Its nearly1200 fellows comprise a sizeable swathe of the UK's medical science leadership. They could be required to declare 
12.
Continue dialogue and engagement with patients and the public their competing interests on the academy website. They could also publicly commit to involving patients in their research, making their data shareable, sharing their data on reasonable request, running their own research teams in ways that promote reliability and transparency, and publishing their research in full, in a timely manner, and in open access journals. The World Health Organization's recent statement on public disclosure of trial results provides a model for how organisations can be asked to sign up to specific recommendations, with clear timescales for audit. 18 The academy had an opportunity to show leadership and independence. But its report says little to unsettle the status quo, suggesting it was not the right group to take on this task. By contrast, the Evidence Manifesto initiative (evidencelive.org/ manifesto/) leaves no room for doubt that there is a crisis in our evidence base and sets out an agenda for radical change. 19 We hope that the UK science and technology committee will pick up its inquiry into research integrity, 6 which was postponed for the general election. As Carl Heneghan, director of the Centre for Evidence Based Medicine in Oxford, said at last week's Evidence Live conference, there is a problem with the E in EBM. If we want the public to trust the evidence, we must make the evidence trustworthy.
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